Speaker:
Title:
Engineering Single Domain Antibody-based CAR T Cells for the Treatment of Solid Tumors
Abstract:
Chimeric antigen receptor (CAR) T cells are a promising cancer therapeutic, as they can specifically redirect the cytotoxic function of a T cell to a chosen target of interest. CAR T cells have been successful in clinical trials against hematological cancers, but have experienced low
efficacy against solid tumors for a number of reasons, including a lack of tumor specific antigens. To treat solid tumors, we aim to develop CARs utilizing single domain antibody fragments (VHHs) that target various aspects of the tumor microenvironment.